The chronic kidney disease (CKD)-hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) market across the seven major markets (7MM*) is forecast to grow at a compound annual growth rate (CAGR) of 4.4% from $2.6 billion in 2024 to $4 billion in 2034, according to GlobalData, a leading data and analytics company.
GlobalData’s latest report “Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia in Chronic Kidney Disease: Opportunity Assessment and Forecast,” reveal that the US dominated the CKD-HPT, HP and HK market in 2024, representing 59.7% of sales in the 7MM. The US is expected to remain as the leading market throughout the forecast period, generating sales of $2.5 billion in 2034 and accounting for 63% of the overall market across the 7MM. This dominating position within the 7MM is a result of the significantly higher costs of marketed products in the US and a high diagnosed prevalence.
Kajal Jaddoo, Senior Pharma Analyst at GlobalData, comments: “While the potential launch of three late-stage pipeline agents will increase the number of pharmacological treatment options available for CKD-HPT and CKD-HP patients, some patients may not benefit from them due to the challenges associated with gaining favorable reimbursement due to their anticipated high annual cost of therapy.”
Key opinion leaders (KOLs) interviewed by GlobalData noted that adherence to phosphate binders remains a big issue, most prominently in relation to the pill burden and pill size of phosphate binders at present.
According to GlobalData forecasts, the overall diagnosed prevalence of CKD-HPT, HP, and HK cases is expected to increase at an annual growth rate (AGR) of 0.86% in the 7MM.
Jaddoo concludes: “Potential barriers to growth of the global CKD-HPT, HP, and HK market include the loss of exclusivity of several key branded products that are expected to face patent and data exclusivity expiration, leading to brand erosion due to the emergence of generics.”
*7MM – The US, France, Germany, Italy, Spain, the UK, and Japan
